All In Biotech

Drug Trial Radar · NCT07229898

A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors

A Phase Ⅰ Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of GEN-725 Tablets in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jan 7, 2025

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase Ⅰ clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of GEN-725 tablets in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • GEN-725 tabletsDrug

    Dose-escalation part: Subjects received GEN-725 tablets at doses of 4, 6 and 8 mg. A single oral dose was administered on Cycle 1 Day 1, observation was conducted for 4 days (i.e., after oral administration of 1 GEN-725 tablet followed by a 4-day washout period), then once daily from Day 5 onward. Dosing occurred with 21 days of continuous treatment per cycle (from Day 5 to Day 25). Dose-expansion part: Subjects received GEN-725 tablets orally at a dose that depends on the outcome of dose-escalation, administered once daily for 21 consecutive days per cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with Dose-Limiting Toxicity (DLT) (Dose-escalation part)Time frame: Day 25
  2. Incidence and severity of adverse events (AEs) (Dose-escalation part)Time frame: From the signing of the Informed Consent Form (ICF) by the subjects until 28±7 days after the last administration of the study drug.
  3. Overall Response Rate (ORR) (Dose-expansion part)Time frame: Up to approximately 24 months.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)

    Jinan, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.